Helene von Roeder reflects on Merck’s Q2 results

Helene von Roeder, Member of the Executive Board and Chief Financial Officer of Merck Group, shared on LinkedIn:

“Our Q2 results were published today! I am pleased to share that we returned to organic sales growth this quarter. This was driven by growth in our Healthcare and Electronics businesses. Life Science also performed as anticipated. While our EBITDA pre remained around stable organically, we remain on track to return to growth in 2024. Here are the key highlights from our results today:

1.      The good performance of Healthcare and Electronics overcompensated for the expected decline in Life Science. This demonstrated again the resilient nature of our diversified business model.

2.      Healthcare once again delivered solid set of numbers, driven by our Oncology as well as Cardiovascular, Metabolism and Endocrinology franchises.

3.      Our Electronics business displayed organic sales growth driven by our Semiconductor Solutions business, resulting, in particular, from the market inflection for AI and advanced nodes.

4.      In Life Science, sales declined as expected due to the continued inventory destocking in Process Solutions. However, we saw order intake in Process Solutions improve sequentially as well as compared to the year-earlier period.

5.      For the second half of 2024, we anticipate that Healthcare will maintain its strong growth momentum. Electronics will continue to benefit from the earlier inflection of the AI and advanced nodes. Therefore, we are raising our 2024 guidance for the Group.

A big shoutout to our entire Merck Group team across the globe for their efforts and commitment. Thanks to you we are confident of achieving our goal: returning to growth in 2024.”

Source: Helene von Roeder/LinkedIn